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Abstract 
 
Background : Corticosteroids are the mainstay of treatment for peritumor edema but are often 
associated with significant sides effects. Therapies that can reduce corticosteroid use would 
potentially be of significant benefit to patients. However, currently there are no standardized 
endpoints evaluating corticosteroid use in neuro-oncology clinical trials. 
Methods : The Response Assessment In Neuro-Oncology (RANO) Working Group has developed 
consensus recommendations for endpoints evaluating corticosteroid use in clinical trials in both 
adults and children with brain tumors. 
Results: Responders are defined as patients with a 50% reduction in total daily corticosteroid 
dose compared to baseline or reduction of the total daily dose to ≤ 2 mg of dexamethasone (or 
equivalent dose of other corticosteroid); baseline dose must be at least 4 mg of dexamethasone 
daily (or equivalent dose of other corticosteroids) for at least one week. Patients must have stable 
or improved Neurologic Assessment in Neuro-Oncology (NANO) score or Karnofsky 
Performance Status score (Lansky score for children age <16 years), and an improved score on a 
relevant clinical outcome assessment tool. These criteria must be sustained for at least 4 weeks 
after baseline assessment to be considered a response, and are confirmed 4 weeks after that (i.e. 
8 weeks after baseline assessment) to be considered a sustained response. 
Conclusions: This RANO proposal for corticosteroid use endpoints in neuro-oncology clinical 
trials may need to be refined and will require prospective validation in clinical studies. 
 
 
Key words: Corticosteroids, peritumor edema, RANO, endpoints 
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Importance of Study 
 
Corticosteroids are the primary treatment for peritumor edema but are associated with significant 
sides effects. Therapies that can reduce corticosteroid use would potentially be of significant 
benefit to patients. Currently there are no standardized endpoints evaluating corticosteroid use in 
neuro-oncology clinical trials. The Response Assessment In Neuro-Oncology (RANO) Working 
Group has developed consensus recommendations for endpoints evaluating corticosteroid use in 
clinical trials in both adults and children with brain tumors. These proposed endpoints will 
hopefully provide consistency in evaluating corticosteroid use across clinical trials but may need 
to be refined and will require prospective validation in clinical studies. 
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I. Introduction 
 
The peritumoral edema associated with brain tumors is an important cause of patient morbidity. 
Corticosteroids are frequently used to manage symptoms from peritumoral edema, but are 
associated with undesirable side effects and reduction in both health-related quality of life 
(HRQoL) and functional status, especially with high doses or prolonged use. Proximal myopathy, 
weight gain and Cushingoid habitus, mood lability, insomnia, hyperglycemia, and 
immunosuppression represent common side effects that may be debilitating and are associated 
with worsened health (Table 1).1-3 
 
With few effective new therapies for brain tumors approved by the U.S. Food & Drug 
Administration (FDA) over the past 30 years,4,5 there has been an ongoing, urgent need to identify 
additional treatments that may improve the lives of these patients.  While overall survival (OS) has 
been the primary endpoint in nearly all neuro-oncology trials, there has been increasing realization 
of the vital role that clinical outcome assessments (COAs) may play in patient-centered drug 
development. COAs can capture outcomes that are meaningful to patients, such as symptoms, 
functional capacity, and other aspects of HRQoL.6-8 Recognizing the negative effects associated 
with prolonged use of corticosteroids common in many brain tumor patients, there is interest in 
identifying a relevant clinical trial endpoint related to reduction in the dependency on 
corticosteroids.  In this Response Assessment in Neuro-Oncology (RANO) Corticosteroids 
Working Group position paper, the committee summarizes key literature on corticosteroid use 
among brain tumor patients, and proposes a new clinical trial endpoint related to corticosteroid use 
and assessment of clinical benefit. 
Arvold - 7 
II. Corticosteroid effects 
 
While corticosteroids represent one of the most common medications used in the management of 
patients with brain tumors, the precise mechanism of action leading to clinical benefit remains 
incompletely understood.  Steroids were first used to alleviate symptoms in patients with brain 
tumors in the 1950’s,9 with reliance specifically on dexamethasone beginning in the 1960’s,10 due 
to its potent glucocorticoid effect and low mineralocorticoid activity, high brain penetration, and 
long biologic half-life.11 For these reasons, dexamethasone is widely considered the corticosteroid 
of choice for patients with brain tumors, which is reflected in consensus guidelines.2,12 
 
The reduction of peritumoral edema by corticosteroids appears to be mediated predominantly by 
a reduction in tumor capillary permeability and cytokine-driven blood-brain barrier (BBB) 
breakdown.  Corticosteroids diffuse through plasma membranes and bind to cytoplasmic receptors, 
leading to nuclear localization and DNA binding to glucocorticoid response elements, affecting 
transcriptional regulation and activating various signaling cascades.13 Tight junction components 
including occludin are upregulated within endothelial cells, contributing to decreased capillary 
permeability.14  Corticosteroids repress pro-inflammatory NF-κB, which has the effect of reducing 
cytokine-driven breakdown of the BBB and local leukocyte recruitment, and also reducing 
transcription of other cytokines including interleukins involved in inflammation.15  Magnetic 
resonance imaging (MRI) studies of patients with brain tumors have demonstrated that 2-3 days 
after dexamethasone administration, there is local reduction in extracellular water content and 
diffusion on MRI, without a decrease in cerebral perfusion, suggesting that reduced local tissue 
pressure may alleviate neurologic symptoms.16,17 Corticosteroids can also reduce tumor 
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enhancement on neuroimaging studies which can confound accurate response assessment. One 
study reported that 90% of patients had a measurable reduction in the size of gadolinium-
enhancing region after introduction of corticosteroids, which was greater than 25% reduction in 
cross-sectional enhancing area in 30% of patients.18 Similarly, corticosteroids can reduce contrast 
enhancement on computerized tomography (CT) images and mimic treatment responses.19 
 
Side effects of corticosteroids are common, oftentimes serious, and increase in likelihood with 
prolonged use or higher dosage.1,3  In one study of primary brain tumor patients, the average 
duration of dexamethasone use was approximately 5 months, with nearly 20% of patients 
remaining on dexamethasone until death.20  Proximal, symmetric myopathy is the most common 
functionally limiting side effect of protracted corticosteroid exposure impacting quality of life, 
with incidence ranging widely from 10% to 90%.21-24 Steroid-related myopathy appears to be 
mediated by apoptosis of skeletal muscle cells induced by corticosteroids, particularly fluorinated 
corticosteroids such as dexamethasone.25  A recent survey conducted by the National Brain Tumor 
Society among patients and caregivers, in which 50% of patients had high-grade gliomas (HGG), 
found that maintaining the ability to walk and perform physical tasks was one of the top priorities 
desired for brain tumor treatments,26 highlighting the potential impact of steroid myopathy.  Mood 
lability, insomnia, and psychiatric manifestations occur in approximately 25% of patients receiving 
dexamethasone,23,27 with the incidence of severe symptoms reported at 6%.27 Weight gain and 
unpleasant cosmetic changes are frequently noted by patients taking corticosteroids. Cushingoid 
features were reported by nearly 75% of physicians assessing 200 brain tumor patients taking a 
mean dexamethasone daily dose of 10 mg for a median of 7 weeks.23  Elevated serum glucose may 
occur in at least 50% of patients taking corticosteroids,20 and is associated with a worse prognosis 
Arvold - 9 
in HGG.28,29 These side effects are only among the most common, and do not include others such 
as immunosuppression-associated infection, arthralgias, avascular necrosis, osteoporosis, 
dyspepsia, visual symptoms, skin changes, and increased risk of venous thromboembolism. In 
addition, there may be potential interactions between corticosteroids and antiepileptic drugs.  The 
Jumpstarting Brain Tumor Drug Development Coalition (JSBTDDC) conducted a workshop with 
the U.S. FDA in 2014 and identified corticosteroid side effects and impact on function as an 
important COA to address.8,30 
 
III. Corticosteroids and survival 
 
Dependence on corticosteroids is independently associated with significantly shorter OS in one 
study; glioma patients undergoing radiotherapy who could discontinue corticosteroids had a 
median ODS of 29 months compared to a median of 5 months in those who were steroid-
dependent.31  Patients in the landmark European Organisation for Research and Treatment of 
Cancer (EORTC)/National Cancer Institute of Canada (NCIC) trial32 who were taking 
corticosteroids at the start of adjuvant therapy had a 36% higher risk of death compared to those 
not taking steroids, after adjustment for other prognostic factors.33 At least two studies have 
reported that baseline steroid use is among the factors most strongly associated with prognosis, in 
addition to patient age and performance status.34,35 
 
It is unclear whether the use of corticosteroids is mechanistically responsible for shorter survival 
among brain tumor patients, or simply a proxy for a larger or more aggressive tumor, or an 
unfavorably-located tumor that cannot be fully resected.  However, there are data suggesting a 
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cytoprotective effect of glucocorticoids in glioma that diminishes the therapeutic efficacy of both 
radiotherapy and chemotherapy.29,36-38 Regardless, most brain tumor trials have inclusion criteria 
requiring a stable or decreasing corticosteroid dose at time of enrollment6,7,32 to reduce bias in the 
comparison between arms, and to ensure the baseline brain MRI or CT scans are valid by 
minimizing any effects of dexamethasone on contrast enhancement or T2/FLAIR abnormality.18,19 
 
IV. Steroid-sparing effects of recent clinical trial agents 
 
Recent neuro-oncology trials using primary endpoints of OS or progression-free survival (PFS) 
have provided illustrative secondary data related to corticosteroid use.  In a secondary analysis of 
the BRAIN trial, a phase II randomized, noncomparative trial of bevacizumab with or without 
irinotecan for adults with recurrent glioblastoma,39 investigators reported that the majority of 
patients in each treatment arm using corticosteroids at baseline were able to reduce their dosage 
during the study.40  Among patients receiving bevacizumab alone, 30% experienced sustained 
reduction in corticosteroid dose, defined as ≥ 50% reduction in corticosteroid dose relative to 
baseline for ≥ 50% of the time while on the study drug, while 16% experienced a complete 
reduction in corticosteroid dose, defined as not using corticosteroids for ≥ 25% of the time on 
study drug.  For patients receiving bevacizumab plus irinotecan, 47% had a sustained reduction in 
corticosteroid dose, and 21% had a complete reduction. While corticosteroid analysis was not a 
primary endpoint in the BRAIN trial, these data emphasized the potential corticosteroid-sparing 
effects of bevacizumab.  Another phase II study among adults with recurrent glioblastoma that 
assessed the activity of cabozantinib41 found that among the 76 patients receiving corticosteroids 
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at baseline, there was a trend toward stable or decreasing corticosteroid doses over time, yet as in 
the BRAIN trial, the study did not contain a corresponding COA to determine patient function. 
 
In addition, several recent drug trials in glioblastoma, while not meeting primary endpoints related 
to survival, showed promising effects on secondary endpoints related to corticosteroid use and 
patient function.  A randomized phase III trial evaluating cediranib, lomustine, or the combination 
of both agents found that mean corticosteroid use decreased by 26% in the cediranib arm (P = .01 
vs. lomustine), decreased by 23% in the combination arm (P = .01 vs. lomustine monotherapy), 
and increased by 5% in the lomustine monotherapy arm.42  In the AVAglio trial of bevacizumab 
vs. placebo for newly diagnosed glioblastoma,6 among patients receiving corticosteroids at 
baseline, corticosteroids were discontinued for at least 5 consecutive days among 66% of patients 
receiving bevacizumab compared to 47% of patients receiving placebo.  Among patients not on 
corticosteroids at baseline, time to initiation of corticosteroids was 12.3 months for bevacizumab 
vs. 3.7 months for placebo (HR = 0.71; 95% CI, 0.57-0.88; P = .002).  Patients who received 
bevacizumab had a longer time with KPS ≥ 70 (9.0 vs. 6.0 months for placebo); however, in both 
this trial and the cediranib trial, it was not clear whether patients with favorable KPS outcomes 
were the same patients with decreased corticosteroid use.  Finally, in the EORTC 26101 trial 
comparing bevacizumab plus lomustine chemotherapy versus lomustine alone in recurrent 
glioblastoma found that among the 50% of patients taking corticosteroids at baseline, 23% of 
patients in the bevacizumab arm were able to stop corticosteroids while on treatment, compared 
with 12% in the control arm. 43, 44 
 
V. Steroid-sparing therapies 
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The best-studied medication with an explicit corticosteroid-sparing effect among brain tumor 
patients, beyond bevacizumab, is corticorelin acetate (Xerecept®), a peptide formulation 
mimicking human corticotropin releasing factor (hCRF). In vivo data from orthotopic glioma 
models demonstrated favorable efficacy and toxicity of corticorelin acetate compared to 
dexamethasone.45 Corticorelin was evaluated in a randomized, placebo-controlled trial of 200 
patients with peritumoral edema from malignant brain tumors, approximately 80% of whom had 
primary brain tumors.23  At baseline, patients enrolled in the trial had stable corticosteroid doses 
of 4-24 mg/day dexamethasone equivalent46 for more than 30 days and had failed ≥ 1 taper, 
experienced ≥ 1 adverse steroid effect, had KPS ≥ 50, and had no anti-cancer treatments planned 
for a 5-week period.  Randomization was to corticorelin (n = 100) vs. placebo (n = 100) for 12 
weeks.  Following randomization, investigators reduced the daily dexamethasone equivalent dose 
by 50% by study week 2, and maintained that dose if possible until week 5, at which point further 
reductions could be made using investigator discretion, with the lowest tolerated dose maintained 
through study week 12.23  The primary endpoint was the percentage of responders at week 2 who 
continued to have response at week 5, with responders defined as patients with at least a 50% 
reduction in dexamethasone equivalent dose from baseline, stable/improved KPS, and 
stable/improved neurologic examination score.23  A secondary endpoint was the proportion of 
patients with improvement in myopathy from baseline to week 12, using the Kendall myopathy 
score (KMS),47 a manual test of muscle strength that scores the proximal muscle groups.  
 
Results from the corticorelin trial showed that at enrollment, mean dexamethasone equivalent dose 
was 9.6 mg daily for a median of 7.1 weeks, with an average of 4 steroid-related adverse effects 
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including myopathy (90% by self-report, 62% by physician report, and 80% by KMS) and 
Cushingoid features (74%).23 The two treatment groups separated numerically early in the study, 
and the primary endpoint demonstrated a trend towards a higher proportion of corticorelin patients 
who were responders at weeks 2 and 5 compared to placebo, at 57% vs. 46%, respectively (P = 
.12) as well as more patients with improved KMS (61% vs. 44%, P = .11).23  At individual 
timepoints including at week 2, 5, and 8, there were more responders in the corticorelin arm (P ≤ 
.03 for all timepoints).  New Cushingoid appearance was also less frequent in the corticorelin 
group (2% vs. 13%, P = .004).23   
 
In a pediatric phase I dose escalation trial of corticorelin, patients <18 years of age with CNS 
tumors and chronically on corticosteroids who had failed prior weaning, received escalating doses 
of corticorelin acetate at doses of 10-60 µg/kg divided twice daily.48 Attempts at reducing 
dexamethasone were initiated after 7 days of therapy.  No dose-limiting toxicity was observed and 
a maximum tolerated dose not defined.  Remarkably, all 14 evaluable patients were able to reduce 
dexamethasone, and 4 patients weaned off completely despite disease progression.  Additional 
analysis showed improved HRQoL, improved physical and emotional functioning, and improved 
sleep/fatigue scores. Despite these promising findings, further development of corticorelin was 
discontinued by the sponsor. 
 
Other agents have also been investigated for their ability to reduce peritumoral cerebral edema and 
corticosteroid requirements.  Based on small prior reports49 postulating an anti-inflammatory effect 
of the frankincense extract Boswellia serrata (BS), a randomized study of BS was conducted 
among 44 brain tumor patients receiving radiotherapy to at least 60% of the brain,50 with a primary 
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endpoint of reduction in edema volume on MRI between baseline and immediately post-
radiotherapy. The trial showed a > 75% reduction in edema volume in 60% vs. 26% of patients 
receiving BS vs. placebo, respectively (P = .023).  While BS was well-tolerated, there was no 
significant impact observed between groups in HRQoL or neurocognitive function, and no 
statistical difference in dexamethasone dose between groups.  In addition, a retrospective study 
examined glioblastoma patients who were taking angiotensin-II inhibitors for hypertension,51 to 
explore whether their use may reduce need for corticosteroids, given putative anti-vascular 
endothelial growth factor (VEGF) properties ascribed to angiotensin-II inhibitors.  Among 87 
glioblastoma patients, 18 were taking angiotensin-II inhibitors at the time of radiotherapy, and 
these patients required only half the corticosteroid use per day during radiotherapy compared to 
the rest of the cohort, on multivariable analysis (P = .005).  Other anti-hypertensives also had a 
steroid-sparing effect, but not to the same degree as angiotensin-II inhibitors. Finally, 
cyclooxygenase-2 (COX-2) inhibitors have also been associated with reduced peritumoral edema 
in at least one in vivo study with a rat brain tumor model,52 and COX-2 inhibitors such as celecoxib 
are sometimes used clinically for steroid-sparing,53 though without strong supporting data. 
 
VI. Response assessment and endpoint development 
 
The trials outlined above highlight some of the key issues relevant to the development of a clinical 
trial endpoint related to corticosteroid reduction.  The results from a 2014 JSBTDDC survey of 
adult patients with brain tumors (n = 839) and their caregivers (n = 985) emphasized that the 
development of a trial endpoint related to corticosteroid use must also contain a COA component, 
rather than only focusing on corticosteroid dose change.8,26,30  When asked to rank the most 
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important goals of future brain tumor treatments aside from prolonging survival, both brain tumor 
patients and their caregivers independently rated “reduction in the need for corticosteroids” as less 
important than alleviation from the neurologic symptoms or conditions listed on the survey, some 
of which are possibly corticosteroid related, such as maintenance of ability to walk and 
performance of basic physical tasks.26 For example, in the corticorelin trial discussed previously, 
the study design incorporated a primary endpoint related to both corticosteroid dose reduction and 
patient function, including KPS and neurologic function score.  
 
The goal of incorporating COAs into clinical trials is to determine whether a drug/intervention can 
be shown to provide a clinically meaningful benefit to patients, such as how a patient feels, 
functions, or survives.  A recently developed Clinician reported outcome measurement (ClinRO) 
instrument that provides a standardized method for reported neurologic exam findings is the 
Neurologic Assessment in Neuro-Oncology (NANO) scale.54 This potentially allows rapid and 
reliable assessment of eight relevant neurologic domains based on direct observation/testing during 
routine office visits, and which demonstrated >90% inter-observer agreement rate in a prospective 
multinational study with kappa statistic ranging from 0.35 to 0.83 (fair to almost perfect 
agreement). 54 However, direct comparison to KPS has not yet been reported. Most valuable to 
patients may be not only preservation of neurologic function, but improvement in specific 
functional domains as corticosteroids are reduced.  For example, given the high priority brain 
tumor patients place on maintaining mobility,26 an explicit measure of steroid-related myopathy 
such as the KMS scale could be integrated as part of a combined endpoint that incorporated both 
objective corticosteroid dose changes along with improvements in KMS.  Other COAs that could 
be incorporated into a combined endpoint with corticosteroid reduction include PRO assessments 
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of neurologic symptoms and HRQoL, such as the M.D. Anderson Symptom Inventory Brain 
Tumor (MDASI-BT) module55 or EORTC QLQ-C30.56  Another potential PRO measure is the 
Dexamethasone Symptom Questionnaire-Chronic (DSQ-C), which is intended to report the 
incidence and severity of side effects over one prior week, and explore changes over time when 
used longitudinally in patients receiving corticosteroids.57 It consists of 17 symptoms and toxicities 
associated with corticosteroid use over time.  In one study, the total cumulative steroid dose 
(steroid dose per day x duration of steroid use in days), after adjusting for age, KPS, and patient 
type, predicted the total DSQ-C score and was associated with increased odds of experiencing 
increased appetite, hiccups, roundness of face, depression, and difficulty rising up from a sitting 
position. 57 In another study, DSQ-C administration appeared feasible over the course of serial 
assessments, and with reasonable agreement between patients and caregiver proxies.58 Ongoing 
research will be required to support the adequacy of the DSQ-C in both the adult and pediatric 
brain tumor population longitudinally, as well as what defines a meaningful change between scores 
over the course of serial examinations. 
 
The U.S. FDA has provided ongoing guidance to investigators and industry59,60 on the 
development of clinical trial endpoints in oncology related to patient-centered outcomes. There is 
an emphasis on the use of well-defined and reliable COA tools and enrollment criteria related to 
the COA domains (such as myopathy, neurologic function scores, or global quality of life scores) 
in addition to capture of the use of concomitant medications (such as corticosteroids).  Of equal 
importance are responder definitions, as outlined succinctly in a study published by authors from 
the FDA and elsewhere on the analogous topic of pain palliation measurement in cancer clinical 
trials.61  Brain tumor treatment strategies that may improve aspects of patient function and reduce 
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corticosteroid requirements are conceptually similar to treatment strategies in other cancers that 
may improve pain control and reduce pain medication dependency, independent of effects on 
overall survival.  The authors suggest a potential approach to defining responders that could be 
translated to neuro-oncology, specifically that a responder would be defined as a patient: 1) with 
a stable or decreasing corticosteroid dose during the clinical trial, in conjunction with, 2) decreased 
symptom burden or increased neurologic functionality that was plausibly related.  Importantly, 
these two changes need to happen in the same patient to thus be classified as a responder. This 
differs from the trials cited above which described corticosteroid reductions or KPS, without 
reporting which patients also had functional/symptomatic improvement. 
 
In the setting of a paucity of new therapies approved for brain tumors in the past few decades, 
stakeholders in the neuro-oncology community met in Bethesda, Maryland in October 2014 to 
discuss patient-centric outcomes that are important to patients beyond survival.8 This included 
members of academia, pharmaceutical companies, the U.S. FDA, brain tumor cooperative groups, 
and importantly, patients.  While OS or PFS have traditionally been the endpoints used to evaluate 
and approve new therapies for brain tumors, the meeting provided a forum to hear from various 
constituencies and weigh the possibility of other clinical trial endpoints that could lead to approval 
of new therapies that improve the lives of brain tumor patients without an explicit goal of extending 
survival.  Regulatory requirements for new drug approval include demonstration of treatment 
benefit, and while evidence of a clinical benefit is often a survival effect in cancer clinical trials, a 
positive impact on how a patient feels or functions on a daily basis is also considered clinically 
beneficial and evidence of such effects would support regulatory approval. 59,60 Therefore, while 
most trials of new therapies could continue to test primarily for survival gains and also examine 
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ancillary patient-function and corticosteroid benefits, other new therapies could be tested explicitly 
for patient-function and corticosteroid benefits without a presumption of increased survival. 
 
VII. Inclusion of corticosteroid use endpoints in brain tumor clinical trials 
 
Based on the FDA guidance “Cancer Drug and Biological Products – Clinical Data in Marketing 
Applications” and recommended best clinical practices, almost all clinical trials include the 
collection of relevant concomitant medications during investigation of an experimental cancer 
therapy.62  Such collection certainly applies to corticosteroid use in ongoing trials for the reasons 
highlighted above and in fact, the use of dexamethasone in brain tumor trials has been cited by the 
FDA as a concomitant medication of particular interest based on its extensive impact on the 
disease.62  Corticosteroid dose is recorded regularly at the time of MRI assessment, since both the 
RANO63 and Macdonald64 criteria require corticosteroid dose in order to fully evaluate imaging 
response, and this provides valuable information about the corticosteroid dose across multiple 
fixed time points. Importantly however, corticosteroid doses are often changed between MRI time-
points in response to neurologic symptoms or toxicities, and such changes may not be accurately 
captured if dosing is queried only at the time of on-study MRI.  A handful of recent studies have 
assessed corticosteroid dose as an endpoint, but have used non-uniform approaches to assess 
corticosteroid use.41,43 
 
Since corticosteroids are taken orally and dose is modified by patients, caregivers, or other health 
care providers, accurate monitoring in the setting of a clinical trial can be challenging.  In the 
similar paradigm of assessing the efficacy of an anti-cancer therapy based on reduction in the use 
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of analgesics while maintaining pain control, a strategy has been to have patients complete a daily 
drug diary documenting all daily doses of analgesic.  The diary is then reviewed with a study team 
member at fixed intervals (i.e., weekly, monthly).  Variations on this approach were applied to 
assess analgesic use in cancer patients as part of a composite endpoint demonstrating patient 
benefit of gemcitabine for pancreatic cancer65 and mitoxantrone/prednisone for hormone-resistant 
prostate cancer.66 For both trials, patient-completed medication diaries were a key element of the 
data presented to support the ultimate approval of these agents for the respective conditions.  Paper 
and pen diaries are still used, yet there is increasing interest in moving to electronic data capture 
given that several studies have demonstrated non-compliance and erroneous data entering with 
non-supervised paper diaries.67,68 Electronic diaries are increasingly available on platforms 
accessible to most patients including smartphones and tablets as well as study-specific devices.  
However, the optimal format, device, and system for data transfer and storage of patient-entered 
electronic data has not yet been determined and is a topic under active discussion at the FDA.  
Although issues of optimizing “e-diaries” for studies moving forward are not yet resolved, it is 
clear that if corticosteroid use is going to be an endpoint in brain tumor trials, trials must include 
standardized procedures for collecting daily corticosteroid dosing via structured diaries and study 
case report forms.  Further, the corticosteroid dosing data must be collected concurrently with 
COA data about symptoms and function to ensure complete and uniform data collection that 
supports pre-planned analyses inclusive of corticosteroid use endpoints. In general, collection 
methods for concomitant medications and COA data must be prospective, pre-specified, 
systematic, and conducted with efforts to minimize missing or incomplete data to allow for 
adequate interpretation. 
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VIII:  Response definition 
 
The proposed approach by the RANO Corticosteroids Working Group is to define a patient as a 
responder during a clinical trial if she/he meets all the following criteria during the trial (Table 2): 
 
1. 50% reduction in total daily corticosteroid dose compared to baseline OR reduction of total 
daily dose to ≤ 2 mg of dexamethasone (or equivalent dose of other corticosteroid); to 
assess response in patients on steroids, baseline dose must be at least 4 mg of 
dexamethasone daily (or equivalent dose of another corticosteroid) for 1 week or more. 
2. Stable or improved NANO score (preferred) or KPS score 
3. Improved score on a relevant COA tool, preferably DSQ-C (once the threshold for 
meaningful change has been established), or possibly MDASI-BT (preferred use of overall 
symptom burden or symptom interference score) or EORTC QLQ-C30/QLQ-BN20 
(preferred use of global health status/QOL subscale), with improvement defined according 
to that tool’s threshold for meaningful change 
4. Criteria #1-3 sustained for at least 4 weeks after baseline assessment to be considered a 
response, and are confirmed 4 weeks after that (i.e. 8 weeks after baseline assessment) to 
be considered a sustained response 
 
For criteria #1 and #4, ‘baseline’ is defined as the average daily dose over the week before the 
study started.  It is recommended that corticosteroid dosing be recorded at each clinical evaluation, 
including any dosing changes related to any clinical event at any point during the trial.  The lowest 
effective dose for a minimum time period required to achieve clinical goals should be prescribed 
Arvold - 21 
among patients on trial, and the dose monitored and adjusted if appropriate at each clinical 
evaluation.  Dosing should generally be administered as a single daily dose given in the morning, 
if possible.  Prior to enrolling a patient on a clinical trial, it is recommended that any pre-existing 
comorbid conditions that may increase the risk of corticosteroid-associated adverse events be 
assessed and treated, if possible. 
 
For criterion #3, different trials could employ different COA tools according to specific study 
hypotheses, as long as the COA tool is suitable for the particular clinical context and the threshold 
for meaningful change has been established. 
 
There are several caveats when applying the above response definition to the pediatric population.  
Currently, the NANO score applies to adult patients only, therefore Lansky or KPS would be used 
for overall assessment.  Additionally, there is a lack of well-defined and reliable pediatric COA 
tools in the pediatric neuro-oncology population, given the heterogeneity in developmental 
abilities and requirements for age-defined instruments.  However, tools such as Patient-Reported 
Outcomes Measurement Information System (PROMIS®)69 are increasingly being incorporated as 
part of pediatric evaluations70-74 and several pediatric instruments are under development.  Their 
use in assessing response in pediatric patients is encouraged although not required at present.   
 
For pediatric patients, therefore, response is defined as (Table 2): 
 
1. 50% reduction in total daily corticosteroid dose compared to baseline OR reduction of total 
daily dose to ≤ physiologic replacement doses of a corticosteroid (e.g. 0.75 mg/ m2/day for 
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dexamethasone); to assess response in patients on steroids, baseline dose must be at least 
1 mg/m2/day of dexamethasone (or equivalent dose of another corticosteroid) for 1 week 
or more. 
2. Stable or improved Performance score (KPS score for age ≥ 16 years or Lansky for age < 
16 years) 
3. Criteria #1-2 are met at least 4 weeks after baseline assessment to be considered a response, 
and confirmed 4 weeks after that (i.e. 8 weeks after baseline assessment) to be considered 
a sustained response 
 
I IX: Conclusion 
 
This working paper from the RANO corticosteroid subcommittee outlines adverse side effects 
experienced by most brain tumor patients who require corticosteroids, and summarizes prior trials 
using corticosteroid-reducing agents. The RANO working group recommends incorporation of a 
new endpoint into neuro-oncology clinical trials related to corticosteroid use and symptom 
burden/functional outcome. The committee proposes a corticosteroid response definition that 
incorporates both reduction in corticosteroid dose and improvement on a COA scale, with 
maintenance of neurologic function, sustained for at least 4 weeks. Implementation into future 
trials will allow validation of these response criteria, with a goal of developing novel therapies that 
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Decreased growth/height (pediatric patients) 
Gastrointestinal Dyspepsia/gastritis 
Hematologic/Immunologic Immunosuppression-related infections 
(oropharyngeal candidiasis, Pneumocystis 




Adrenal insufficiency (after discontinuation) 
Cutaneous or Vascular Acne 
Striae 
Purpura 
Delayed wound healing 
Peripheral edema 
Ocular Visual blurring 
Cataract formation 
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Table 2. Criteria for determining response related to corticosteroids during a clinical 
trial (must meet all criteria) 
 
Adult patients 1. 50% reduction in total daily corticosteroid dose compared to 
baseline* OR reduction of total daily dose to ≤ 2 mg of 
dexamethasone (or equivalent dose of other corticosteroid); 
baseline dose must be at least 4 mg of dexamethasone daily (or 
equivalent dose of other corticosteroid) 
2. Stable or improved NANO score (preferred) or KPS or ECOG 
score 
3. Improved score on a relevant COA tool, preferably DSQ-C 
(once the threshold for meaningful change has been 
established), or possibly MDASI-BT (preferred use of overall 
symptom burden or symptom interference score) or EORTC 
QLQ-C30/QLQ-BN20 (preferred use of global health 
status/QOL subscale), with improvement defined according to 
that tool’s threshold for meaningful change 
4. Criteria #1-3 sustained for at least 4 weeks after baseline 
assessment to be considered a response, and are confirmed 4 
weeks after that (i.e. 8 weeks after baseline assessment) to be 
considered a sustained response 
 
Pediatric patients 1. 50% reduction in total daily corticosteroid dose compared to 
baseline OR reduction of total daily dose to ≤ physiologic 
replacement doses of a corticosteroid (e.g. 0.75 mg/ m2/day for 
dexamethasone); baseline dose must be at least 1 mg/m2/day of 
dexamethasone (or equivalent dose of other corticosteroid) 
2. Stable or improved Performance score (KPS or ECOG score for 
age ≥ 16 years or Lansky for age < 16 years) 
3. Criteria #1-2 are met at least 4 weeks after baseline assessment 
to be considered a response, and confirmed 4 weeks after that 
(i.e. 8 weeks after baseline assessment) to be considered a 
sustained response 
 
Abbreviations: NANO, Neurologic Assessment in Neuro-Oncology51; KPS, Karnofsky 
performance status; COA, clinical outcome assessment; DSQ-C, Dexamethasone Symptom 
Quesitonnaire-Chronic54; MDASI-BT, M.D. Anderson Symptom Inventory Brain Tumor52; 
EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire53; QOL, quality of life. 
* ‘Baseline’ is defined as the average daily dose over the week before the study started. 
** Different trials could employ different COA tools according to specific study hypotheses, 
as long as the COA tool is suitable for the particular clinical context and the threshold for 
meaningful change has been established. 
 
 
 
